Cargando…

DIPG-61. RESCUE REGIMENS AFTER BIOMEDE: POSSIBLE INFLUENCE ON OS ASSESSMENT

BIOMEDE is a multicentric randomized phase II trial to evaluate in DIPG the OS of patients treated with dasatinib, erlotinib or everolimus. The OS is the result of the first line treatment but it could also be affected by re-irradiation and the second line treatment received after progression, espec...

Descripción completa

Detalles Bibliográficos
Autores principales:	Carlo, Daniela Di, Pommier, Bertille, Teuff, Gwenael Le, Abbou, Samuel, Berlanga, Pablo, Geoerger, Birgit, Puget, Stephanie, Beccaria, Kevin, Blauwblomme, Thomas, Debily, Marie-Anne, Castel, David, Lechapt, Emmanuelle, Varlet, Pascale, Dangouloff-Ros, Volodia, Boddaert, Nathalie, Vassal, Gilles, Deley, Marie-Cécile Le, Grill, Jacques
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2020
Materias:	Diffuse Midline Glioma/DIPG
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7715765/ http://dx.doi.org/10.1093/neuonc/noaa222.106

Ejemplares similares

DIPG-35. BIOLOGICAL MEDICINE FOR DIFFUSE INTRINSIC PONTINE GLIOMA (DIPG) ERADICATION: RESULTS OF THE THREE ARM BIOMARKER-DRIVEN RANDOMIZED BIOMEDE 1.0 TRIAL
por: Grill, Jacques, et al.
Publicado: (2020)

DIPG-58. HISTONE H3 WILD-TYPE DIPG/DMG OVEREXPRESSING EZHIP EXTEND THE SPECTRUM OF DIFFUSE MIDLINE GLIOMAS WITH PRC2 INHIBITION BEYOND H3-K27M MUTATION
por: Castel, David, et al.
Publicado: (2020)

DIPG-56. EXPLORATION OF TUMOR/STROMA INTERACTIONS IN DIPG XENOGRAFT BY SPECIES-SPECIFIC RNA-SEQ DECONVOLUTION INDICATES A ROLE OF MICROGLIA CELL IN DIPG DEVELOPMENT
por: Merlevede, Jane, et al.
Publicado: (2020)

DIPG-38. PATIENT-DERIVED THREE-DIMENSIONAL AVATARS REVEAL CELL-AUTONOMOUS MECHANISMS DRIVING INVASION AND METASTATIC PROGRESSION IN DIFFUSE MIDLINE GLIOMAS
por: Bruschi, Marco, et al.
Publicado: (2023)

DIPG-74. RE-IRRADIATION OF DIPG: DATA FROM THE INTERNATIONAL DIPG REGISTRY
por: Lafay-Cousin, Lucie, et al.
Publicado: (2020)

DIPG-16. Evaluation of myeloid component of DIPG microenvironment
por: Mishra, Deepak, et al.
Publicado: (2022)

DIPG-03. Therapeutic targeting of purine biosynthesis in DIPG
por: Mersich, Ian, et al.
Publicado: (2022)

DIPG-46. NON-DIPG PATIENTS ENROLLED IN THE INTERNATIONAL DIPG REGISTRY: HISTOPATHOLOGIC EVALUATION OF CENTRAL NEURO-IMAGING REVIEW
por: Lazow, Margot A, et al.
Publicado: (2020)

DIPG-20. DETERMINATION AND MANAGEMENT OF HYDROCEPHALUS IN PATIENTS WITH DIPG, AN INSTITUTIONAL EXPERIENCE
por: Fonseca, Adriana, et al.
Publicado: (2020)

DIPG-70. DISORDERED DNA METHYLATION IN DIPG UNDERLIES PHENOTYPIC PLASTICITY
por: Koldobskiy, Michael, et al.
Publicado: (2020)

DIPG-59. UPREGULATION OF PRENATAL PONTINE ID1 SIGNALING IN DIPG
por: Harris, Micah K, et al.
Publicado: (2020)

DIPG-57. TRANSCRIPTOMIC AND PROTEOMIC ANALYSES OF DIPG RESPONSE TO ONC201
por: Sridharan, Sreepradha, et al.
Publicado: (2020)

DIPG-12. TARGETING EPIGENETIC MODIFIERS TO INDUCE IMMUNE SIGNALING IN DIPG
por: Tetens, Ashley, et al.
Publicado: (2020)

DIPG-52. Activators of the integrated stress response synergize to kill DIPG
por: Novak, Orlandi, et al.
Publicado: (2022)

DIPG-43. CLINICAL AND MOLECULAR CHARACTERISTIC OF A NEW SUBTYPE OF DMG, H3K27-ALTERED WITH MAPK-ACTIVATING CO-DRIVER MUTATIONS
por: Auffret, Lucie, et al.
Publicado: (2023)

DIPG-23. SINGLE CASE REPORT OF LOW DOSE RADIOTHERAPY AND CHEMOTHERAPY IN THE TREATMENT OF DIPG
por: Tseng, Chen Kan, et al.
Publicado: (2020)

DIPG-40. TARGETING MASTER REGULATOR DEPENDENCIES IN DIFFUSE INTRINSIC PONTINE GLIOMA (DIPG)
por: Pavisic, Jovana, et al.
Publicado: (2020)

DIPG-37. Exploring the role of the epigenetic factor H2A.Z acetylation in DIPG
por: Sanguino, Yolanda Colino, et al.
Publicado: (2022)

DIPG-28. REPEATED LOW DOSE RT FOR PEDIATRIC DIPG – LESS DISEASE BURDEN WITH COMPARABLE OUTCOMES
por: Wu, Yao Yu, et al.
Publicado: (2020)

DIPG-32. AKT SIGNALING DRIVES RESISTANCE TO ONC201 IN DIFFUSE INTRINSIC PONTINE GLIOMA (DIPG)
por: Jackson, Evangeline R, et al.
Publicado: (2020)

DIPG-27. Behavioral disturbances as underestimated presenting symptoms in children with Diffuse Intrinsic Pontine Glioma (DIPG)
por: Milanaccio, Claudia, et al.
Publicado: (2022)

DIPG-21. DIPG cells alter the permeability of the blood-brain barrier in the brainstem leading to treatment failure.
por: Ung, Caitlin, et al.
Publicado: (2022)

DIPG-53. CHARACTERIZING THE ROLE OF PPM1D MUTATIONS IN THE PATHOGENESIS OF DIFFUSE INTRINSIC PONTINE GLIOMAS (DIPGS)
por: Khadka, Prasidda, et al.
Publicado: (2020)

DIPG-16. COMBINATION OF ARGININE DEPLETION AND POLYAMINE INHIBITION AS AN ANTICANCER STRATEGY FOR DIFFUSE INTRINSIC PONTINE GLIOMA (DIPG)
por: Khan, Aaminah, et al.
Publicado: (2020)

DIPG-38. ADDITION OF MULTIMODAL IMMUNOTHERAPY TO COMBINATION TREATMENT STRATEGIES FOR CHILDREN WITH DIPG: FINAL RESULTS OF A COHORT OF CHILDREN
por: Van Gool, Stefaan, et al.
Publicado: (2020)

DIPG-13. TARGETING HYPOXIA AND MITOCHONDRIA WITH REPURPOSED METABOLIC DRUGS AS AN APPROACH TO RADIOSENSITIZATION FOR DIFFUSE INTRINSIC PONTINE GLIOMAS (DIPG)
por: Shen, Han, et al.
Publicado: (2020)

DIPG-07. HIGH THROUGHPUT DRUG SCREENING IDENTIFIES POTENTIAL NEW THERAPIES FOR DIFFUSE INTRINSIC PONTINE GLIOMAS (DIPGs)
por: Upton, Dannielle, et al.
Publicado: (2020)

DIPG-42. TOWARD MULTIMODALITY THERAPY FOR DIPG/DMG: DEVELOPMENT AND INVESTIGATION OF CRANIOSPINAL IRRADIATION AND CONVECTION-ENHANCED DELIVERY PDX MODELS
por: Knox, Aaron J, et al.
Publicado: (2020)

DIPG-83. USING COPPER CHELATING AGENTS TO TARGET RECEPTOR TYROSINE KINASE SIGNALLING IN DIFFUSE INTRINSIC PONTINE GLIOMA (DIPG)
por: Michniewicz, Filip, et al.
Publicado: (2020)

DIPG-73. SENESCENCE ASSOCIATED SECRETORY PHENOTYPE AS A MECHANISM OF RESISTANCE AND THERAPEUTIC VULNERABILITY IN BMI1 INHIBITOR TREATED DIPG
por: Balakrishnan, Ilango, et al.
Publicado: (2020)

DIPG-71. SELECTIVE HDAC INHIBITOR RG2833 INDUCES DIPG CELL DEATH VIA DOWNREGULATION OF THE NFĸB PATHWAY
por: Barnett, Katherine, et al.
Publicado: (2020)

DIPG-20. Copper chelation therapy targets S-adenosylmethionine (SAM) metabolism and epigenetic regulators in diffuse intrinsic pontine glioma (DIPG)
por: Michniewicz, Filip, et al.
Publicado: (2022)

DIPG-18. Evaluating drug distribution in children with diffuse intrinsic pontine glioma (DIPG) treated with convection-enhanced drug delivery
por: Szychot, Elwira, et al.
Publicado: (2022)

DIPG-14. TARGETING POLO-LIKE KINASE 1 IN COMBINATION WITH KEY ONCOGENIC DRIVERS IN DIPG: FROM SINGLE AGENT TO COMBINATION STRATEGIES
por: Franshaw, Laura, et al.
Publicado: (2020)

DIPG-02. Role of a Bevacizumab-based regime in the treatment of children with diffuse intrinsic pontine glioma (DIPG): a systematic review
por: Evans, Mia, et al.
Publicado: (2022)

DIPG-55. PATTERNS OF CEREBROSPINAL FLUID DIVERSION AND SURVIVAL IN CHILDREN WITH DIFFUSE INTRINSIC PONTINE GLIOMA: A REPORT FROM THE INTERNATIONAL DIPG REGISTRY
por: Cooney, Tabitha, et al.
Publicado: (2020)

DIPG-49. BRAINSTEM AND PONTINE VOLUMETRIC ANALYSIS AS A SURROGATE MEASURE OF LOCAL DISEASE CONTROL IN CHILDREN WITH DIFFUSE INTRINSIC PONTINE GLIOMA (DIPG)
por: Bander, Evan D, et al.
Publicado: (2020)

DIPG-52. PHASE I CLINICAL TRIAL OF ONC201 IN PEDIATRIC H3 K27M-MUTANT GLIOMA OR NEWLY DIAGNOSED DIPG
por: Gardner, Sharon, et al.
Publicado: (2020)

DIPG-62. Reducing the levels of genomic 5-hydroxymethylcytosine by inhibiting the TET pathway induces apoptosis and decreases proliferation in Diffuse Intrinsic Pontine Glioma (DIPG)
por: Parthasarathy, Akhila, et al.
Publicado: (2022)

DIPG-11. DIPGs show robust MHC class I expression but low lymphoid and high myeloid infiltration partly reversible by DNA methyltransferase inhibition
por: Mishra, Deepak, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_n3lckfjngi33gds8ivimnhvpb2